Compass says depression drug has long-lasting benefits
Compass Pathways reports six-month data confirming the rapid and durable effects of its psilocybin-based depression treatment.
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Compass Pathways has released six-month data from its second Phase 3 trial (COMP006) for a depression drug. The company reports that the treatment maintains a rapid and durable profile over this period.
Coverage from STAT, Endpoints News, and Business Wire emphasizes the durability of the drug's benefits. Moomoo reports that company shares gained following the release of this late-stage trial data.
According to Psychedelic Alpha, the company is eyeing a launch in the first half of 2027. Endpoints News notes that these results come ahead of a filing planned for the end of the year.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 6h ago.
Quick answers
What specific data was released by Compass Pathways?
The company announced six-month data from its second Phase 3 trial, COMP006, confirming a rapid and durable profile for its depression treatment.
When does the company plan to launch the drug?
Compass Pathways is eyeing a launch in the first half of 2027.
What is the nature of the drug being tested?
According to Endpoints News, it is a psilocybin drug used to treat depression.
Coverage (7)
- COMP360 Psilocybin Sustains Depression Benefit Through 26 Weeks HCPLive · 1d ago
- Compass Pathways Is Maintained at Buy by BTIG Moomoo · 1d ago
- Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile Business Wire · 1d ago
- Compass Pathways Shares Gain on Positive Late-Stage Trial Data for Depression Treatment Moomoo · 1d ago
- Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch Psychedelic Alpha · 1d ago
- Updated: Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing Endpoints News · 1d ago
- Compass says depression drug has long-lasting benefits STAT · 1d ago broke it first
People, places & organizations
Topics
Related trends
Stock market today: Nasdaq pares losses, Dow and S&P 500 fall as oil jumps amid US-Iran tensions
AI chip maker SambaNova raises $1B at $11B valuation, 5 months after last mega round
AI chip startup SambaNova has secured $1 billion in new funding, reaching an $11 billion valuation just five months after its previous mega round.
Famed permabear warns SpaceX IPO could be laughed at in 50 years, 'craziest' market bet for Main Street
Oil Prices Jump After Trump Says Deal With Iran Is ‘Over’
UniCredit Nears Control of Commerzbank After Takeover Push
UniCredit has secured a 48% stake in Commerzbank, bringing the Italian lender closer to full control of the German institution.